Siemens Healthcare has received FDA clearance for their MAMMOMAT Inspiration Prime Edition lower dose mammography system.
Siemens Healthcare has received FDA clearance for their MAMMOMAT Inspiration Prime Edition mammography system, which lowers radiation dose by up to 30 percent, the company said.
This latest MAMMOMAT system reduces dose by replacing the standard scatter radiation grid with a new algorithm for progressive image reconstruction, according to Siemens. The algorithm can identify scatter-causing structures and calculating a corrected image. This may enable the complete use of primary radiation to achieve lower dose, the company said.
The design of the MAMMOMAT Inspiration Prime Edition obviates the need for a grid, the company said, and lower doses compared to the predecessor model are needed for high-quality images. This edition is based the MAMMOMAT Inspiration platform which has been used since 2007.
AI-Initiated Recalls After Screening Mammography Demonstrate Higher PPV for Breast Cancer
March 18th 2025While recalls initiated by one of two reviewing radiologists after screening mammography were nearly 10 percent higher than recalls initiated by an AI software, the AI-initiated recalls had an 85 percent higher positive predictive value for breast cancer, according to a new study.
ECR Mammography Study: Pre-Op CEM Detects 34 Percent More Multifocal Masses than Mammography
February 28th 2025In addition to contrast-enhanced mammography (CEM) demonstrating over a 90 percent detection rate for multifocal masses, researchers found that no significant difference between histological measurements and CEM, according to study findings presented at the European Congress of Radiology.
Study: Mammography AI Leads to 29 Percent Increase in Breast Cancer Detection
February 5th 2025Use of the mammography AI software had a nearly equivalent false positive rate as unassisted radiologist interpretation and resulted in a 44 percent reduction in screen reading workload, according to findings from a randomized controlled trial involving over 105,000 women.